Sunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results a...
February 28 2019 - 6:00AM
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that
it will host a conference call on Thursday, March 7th, 2019 at 4:30
p.m. Eastern Time to discuss corporate updates and financial
results for the fourth quarter and year ended December 31, 2018.
The call can be accessed by dialing (844)
296-7720 (U.S. and Canada) or (574) 990-1148 (international) and
entering passcode 6225859.
To access the live audio webcast, or the
subsequent archived recording, visit the "Investors and Media -
Calendar of Events" section of the Sunesis website at
http://ir.sunesis.com. The webcast will be recorded and available
for replay on the company's website for two weeks.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new therapeutics for the treatment of hematologic and
solid cancers. Sunesis has built an experienced drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel kinase
inhibitor pipeline, with an emphasis on its oral non-covalent BTK
inhibitor vecabrutinib. Vecabrutinib is currently being evaluated
in a Phase 1b/2 study in adults with chronic lymphocytic leukemia
and other B-cell malignancies that have progressed after prior
therapies. The Company’s proprietary PDK1 inhibitor SNS-510 is in
preclinical development. PDK1 is a master kinase that activates
other kinases important to cell growth and survival including
members of the AKT, PKC, RSK, and SGK families. Sunesis is
exploring strategic alternatives for vosaroxin, a late-stage
investigational product for relapsed or refractory AML. Sunesis
also has an interest in the pan-RAF inhibitor TAK-580 which is
licensed to Takeda. TAK-580 is in a clinical trial for pediatric
low-grade glioma.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
Investor and Media
Inquiries: |
|
|
Maeve Conneighton |
Willie
Quinn |
|
Argot Partners |
Sunesis
Pharmaceuticals Inc. |
|
212-600-1902 |
650-266-3716 |
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles